Beam Therapeutics Inc.
https://beamtx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Beam Therapeutics Inc.
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
CRISPR Therapeutics And Vertex’s CRISPR Breakthrough: How And Why They Got There First
Leaders from the companies explain how they navigated to success with the world’s first CRISPR-based medicine – and avoided the pitfalls that claimed other programs.
Verve’s Cholesterol Gene Editing Hits Milestone – With Lilly Now Onboard
The gene-editing company has achieved proof-of-concept for its base-editing platform in three patients – but safety concerns have sent its share price into decline.
Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Guide Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice